NRIX Nurix Therapeutics, Inc.

Nurix Reports Positive Phase 1 Trial Data for Bexobrutideg in Leukemia (CLL/SLL)

Nurix Therapeutics announced updated positive clinical data from its Phase 1a/1b study of bexobrutideg (NX-5948), a BTK degrader, in patients with relapsed or...